CORE--IMAGING AND DOSIMETRY

核心A成像和剂量学，将为该计划提供4个支持领域 项目。这些措施包括(1)提供动物和临床成像， (2)利用Adapt II和SAAM建立抗体药代动力学模型 软件，(3)吸收辐射剂量估算，(4)计数 放射分析中的质量保证。图像为疾病提供了指南 范围、扩散和手术治疗。此外，他们是主要的 输入以评估患者的器官和肿瘤摄取。 建模是必要的，因为我们需要In-111单抗的生物分布 代表后续的Y-90 Mab；因此，我们使用图像数据作为 用于预测治疗应用的生物分布的建模者的输入 病人。我们将比较器官摄取和肿瘤摄取的模型预测 手术样本。辐射剂量是使用该模型的 单个器官摄取时间-活动积分。这样的剂量估计将 与血细胞水平等临床数据进行比较。最后， 计数实验的质量保证将由核心A确定。 成像和剂量学核心将继续为王博士提供支持， 吴医生和施弗利医生。此外，我们将保持我们的密切合作 与Raubitschek博士和Maryon博士的关系。另外， 该核心将为动物提供成像和剂量估计服务 学习。外部协作将继续与AAPM任务组7和 田纳西州橡树岭的骑行中心(迈克·斯塔宾饰)

Core A Imaging and Dosimetry, will provide 4 support ares to the Program Project. These include (1) the provision of animal and clinical imaging, (2) modeling of antibody pharmacokinetics using ADAPT II and SAAM software, (3) estimation of absorbed radiation doses, and (4) counting quality assurance in radioassays. Images provide a guide to disease extent, spread and surgical treatment. In addition, they are the primary input into the estimation of organ and tumor uptake in the patient. Modeling is needed since we require biodistributions of in-111 Mabs to stand in for the subsequent Y-90 Mab; thus, we use the image data as the modeler's input to predict the therapy application's biodistribution in patients. We will compare model predictions of organ and tumor uptake with surgical samples. Radiation dose is estimated using the model's individual organ uptake time-activity integrals. Such dose estimates will be compared with clinical data such as blood cell levels. Finally, counting experiment quality assurance will be determined from Core A. The Imaging and Dosimetry core will continue to provide support to Dr. Wong, Dr. Wu and Dr. Shively. In addition, we will maintain our close association with Dr. Raubitschek 1) as well as Dr. Maryon. Additionally, this Core will provide imaging and dose estimation service for the animal studies. External collaborations will continue with AAPM Task Group 7 and the RIDIC center at Oak Ridge TN (Mike Stabin).